RB-105

N/A

Report date: 2022/01/14 13:23:58

NME

Base Information

Drug NameRB-105

Drug Alias NameS-21402S-21402-1RB-105

ClassificationSmall molecules > Heterocyclic drugs

Mechanisms of ActionAngiotensin-converting enzyme inhibitorsNeuronal acetylcholine receptor protein alpha-7 subunit antagonists

TargetsNeuronal acetylcholine receptor protein alpha-7 subunitAngiotensin-converting enzyme

Therapy Area/IndicationsHypertension

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusDiscontinued (Phase 1 Clinical)

Highest Status in ChinaN/A

Originator CompaniesSanofi Inserm

China Registration ClassN/A

Active CompaniesN/A

Inactive CompaniesInserm Sanofi

Active IndicationsN/A

Inactive IndicationsHypertension

ATC CodeN/A